Enliven Therapeutics, Inc.

1. 01

   Ahead of SPY and its sector fund XLV over 1 year

   1 month: +11.5% (SPY −1.6%, XLV +13.5%). 3 months: −20.9% (SPY −0.4%, XLV +15.5%). 1 year: +148.6% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: ELVN, SPY and XLV · as of 4 Nov 2026

2. 02

   Below its 50-day average, above its 200-day

   The 4 Nov 2026 close of $47.25 was 1.1% below its 50-day average ($47.80) and 9.8% above its 200-day average ($43.02). It has closed above the 200-day for 7 sessions, since 27 Oct 2026. The 50-day average crossed above the 200-day on 20 Jan 2026, 200 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

3. 03

   7.5 days to cover short interest

   9.3M shares were sold short at the 15 Oct 2026 settlement, 12.7% of the 73.3M shares outstanding; covering them would take 7.5 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

4. 04

   68% of the way up its 52-week range

   Closed at $47.25 on 4 Nov 2026: 24.2% below the 52-week high of $62.32 (5 Aug 2026) and 219.6% above the low of $14.79 (6 Jan 2026).

   Daily price bars, split-adjusted · as of 4 Nov 2026

5. 05

   Volume 1.8× its 30-session average on 4 Nov 2026

   4 Nov 2026 volume of 2.7M shares was 1.8× the average of the 30 sessions before it (1.5M), as the price rose 5.4%. SPY traded 1.5× its own average that session.

   Daily volume against a 30-session baseline · as of 4 Nov 2026

At the 4 Nov 2026 close